OM DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages Outset Medical, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action – OM

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Outset Medical, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from September 15, 2020, to August 7, 2024 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by October 28, 2024, to serve as lead plaintiff [1] Group 2: Allegations Against Outset Medical - The lawsuit alleges that Outset Medical made false and misleading statements regarding the FDA clearance for the TabloCart, which was not obtained [3] - It is claimed that Outset promoted continuous renal replacement therapy (CRRT) as FDA-approved for the Tablo, which was inaccurate [3] - The company reportedly lacked the necessary sales team and processes to effectively ramp up Tablo sales [3] - Allegations include inadequate internal controls leading to improper marketing and misleading financial statements [3] - The lawsuit asserts that the positive statements made by the defendants about the company's business were materially misleading [3]